Specifically, we conducted the current NMA to evaluate the potentially different risk of colorectal tumors related to GLP-1 receptor agonists and SGLT2 inhibitors prescription in subjects without baseline colorectal tumors. The gene discussed is GLP1R; the disease is colorectal neoplasm.